Eleven percent of the US population has taken GLP-1 drugs for diabetes or weight reduction, and, as a result, have been spending less on food and consuming fewer calories
The cagrilintide component addresses appetite and satiety through amylin signaling, while retatrutide simultaneously optimizes glucose metabolism, energy expenditure, and fat oxidation through its triple mechanism
Antioxidants help fight free-radical molecules
Weight gain A potential side effect of regular insulin use due to improved blood sugar control and increased calorie storage
Both medications are typically introduced gradually over a dosage schedule
Silva DF, Empadinhas N, Cardoso SM, Esteves AR (2022) Neurodegenerative microbially-shaped diseases: oxidative stress meets neuroinflammation